Ask about this productRelated genes to: FLJ11730 antibody
- Gene:
- MEAF6 NIH gene
- Name:
- MYST/Esa1 associated factor 6
- Previous symbol:
- C1orf149
- Synonyms:
- NY-SAR-91, FLJ11730, Eaf6, CENP-28
- Chromosome:
- 1p34.3
- Locus Type:
- gene with protein product
- Date approved:
- 2005-07-13
- Date modifiied:
- 2016-10-05
Related products to: FLJ11730 antibody
Related articles to: FLJ11730 antibody
- The causal impact of fine particulate matter (PM), an established environmental risk factor, on childhood asthma and its biological mechanisms remain to be elucidated. The objective of the present study was to evaluate the causal association between PM and childhood asthma and to dissect the mediating role of plasma proteins through a multi-omics integrated Mendelian randomisation (MR) framework. - Source: PubMed
Publication date: 2026/09/01
Li HuaRen XiaotaoLei XiaopingLi YiDong Wenbin - Ossifying fibromyxoid tumor (OFMT) is a rare mesenchymal neoplasm of uncertain lineage of differentiation driven by a broad spectrum of gene fusions. It manifests primarily in soft tissues of the extremities. In this study, we performed a comprehensive clinicopathological, molecular-genetic, and epigenetic analysis of 70 cases of OFMT, with a specific focus on rare fusion subtypes, particularly ZC3H7B::BCOR, PHF1::TFE3, and MEAF6::PHF1. In addition, we included 7 tumors with novel fusions, namely, AFF3::PHF1, PHF1::KLF15, PHF1::PRKAG1, CREBBP::PHF1, EPC1::BMI1, MEAF6::BCOR, and EP300::BCORL1. The clinicopathological characteristics revealed a correlation between specific fusions and aggressive clinical behavior; notably, tumors with ZC3H7B::BCOR fusions were always classified as morphologically atypical or malignant and were associated with significantly higher recurrence and metastatic rates compared with other fusion groups, particularly EP400::PHF1. Immunohistochemical analysis further revealed a distinct immunophenotype in the ZC3H7B::BCOR group. Whereas immunopositivity for cytokeratins and myogenic markers was observed in approximately one-quarter and more than one-third of OFMT cases overall, respectively, ZC3H7B::BCOR-rearranged tumors were negative for both. In contrast, the majority showed immunopositivity for pan-Trk. Additionally, DNA methylation profiling distinguished ZC3H7B::BCOR-rearranged cases from other fusion-positive OFMT cases. The former group clustered closely with a subset of high-grade endometrial stromal sarcomas. This study supports the recognition of ZC3H7B::BCOR-positive tumors as a distinct clinicopathological entity, contributing to the refined molecular taxonomy of this neoplasm. - Source: PubMed
Publication date: 2026/06/16
Klubíčková NatálieDermawan Josephine KAmeline BaptisteMartínek PetrVaněček TomášHájková VeronikaPtáková NikolaGrossmann PetrŠteiner PetrKormunda StanislavPerret Raul ELe Loarer FrançoisDehner Carina ATorres-Mora JorgeGross John MChrisinger John S ACharville GregoryKösemehmetoĝlu KemalWangsiricharoen SintawatMeis JeanneŠpůrková ZuzanaZámečník MichalStaniczková Zambo IvaKlinger Tomᚊvajdler MariánKinkor ZdeněkMichalová KvětoslavaBaumhoer DanielMichal MichalAntonescu Cristina RMichal Michael - - Source: PubMed
Publication date: 2026/05/22
Lai Jonathan KFadel ElieLacouline-Boulanger RoxanneLaguë NadineNwilati HanadTessier-Cloutier BasileRahimi Kurosh - The histone acetyltransferase complex HBO1 (KAT7) is an oncogenic regulator across multiple cancers, promoting cell proliferation and migration. Though clinically important, no targeted therapies address HBO1 dysregulation. HBO1 forms complexes with MEAF6, JADE(1/2/3), ING(ING4/5), and BRPF1/2/3 to acetylate histones H3 and H4, especially at H3K14, promoting transcriptional activation and genomic stability. It colocalizes with active transcriptional sites and participates in gene regulation, DNA repair and replication. Most HBO1-associated cancer mutations are missense, though their effects remain unclear. Silencing HBO1 restores normal proliferation and gene expression, underscoring its oncogenic role. HBO1 activity supports cancer pathways, including apoptosis resistance, DNA damage response, and cell cycle regulation. The HBO1 inhibitor WM-3835 disrupts H3K14 acetylation, reducing tumor growth in several cancers. This review provides insights into the function of HBO1 in cancer, especially in histone acetylation, ubiquitination, stem cell maintenance, and pro- and anti-oncogenic signaling. Understanding the roles of HBO1 may guide new epigenetic therapies for HBO1-driven malignancies. - Source: PubMed
Publication date: 2026/01/18
Marchione Alissa DKathrein Katie L - Ossifying fibromyxoid tumor (OFMT) is a rare mesenchymal neoplasm first described in 1989. It typically arises in the superficial soft tissues of the extremities as a slow-growing, painless mass. Histologically, it is commonly characterized by a multilobular architecture composed of uniform epithelioid cells embedded in a fibromyxoid matrix, often surrounded by a rim of metaplastic bone. While classic cases are readily identifiable, the tumor's histopathological heterogeneity can mimic a range of benign and malignant neoplasms, posing significant diagnostic challenges. Molecularly, most OFMTs harbor PHF1 rearrangements, commonly involving fusion partners such as EP400, MEAF6, or TFE3. This review underscores the importance of an integrated diagnostic approach- incorporating histopathological, immunohistochemical, and molecular data- to accurately classify OFMT and distinguish it from its mimics. Expanding awareness of its morphologic and molecular spectrum is essential for precise diagnosis, optimal patient management, and a deeper understanding of this enigmatic neoplasm. - Source: PubMed
Publication date: 2026/01/14
Chatzopoulos KyriakosSyrnioti AntoniaYakoub MohamedLinos Konstantinos